Microbot Medical Publishes ACCESS-PVI Feasibility Study of LIBERTY Robotic System in JVIR
Microbot Medical’s ACCESS-PVI pivotal study of its single-use LIBERTY Endovascular Robotic System was published in the Journal of Vascular and Interventional Radiology after peer review of 2025 feasibility data. The LIBERTY system, FDA-cleared in September 2025, entered limited release last year with full rollout at the April 2026 SIR conference.
1. JVIR Publication Milestone
Microbot Medical’s ACCESS-PVI pivotal study has been rigorously peer-reviewed and published in the Journal of Vascular and Interventional Radiology, validating the company’s multicenter feasibility data for the LIBERTY system.
2. ACCESS-PVI Study Background
The multicenter feasibility study, led by Dr. Francois Cornelis and completed in 2025, evaluated safety and efficacy of the disposable LIBERTY Endovascular Robotic System for peripheral vascular interventions.
3. Regulatory and Market Progress
The LIBERTY system received FDA clearance in September 2025 and entered limited market release last year, with plans for a full commercial rollout at the Society of Interventional Radiology conference in April 2026.